|
Gene: TBX10 |
Gene summary for TBX10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TBX10 | Gene ID | 347853 |
Gene name | T-box transcription factor 10 | |
Gene Alias | TBX13 | |
Cytomap | 11q13.2 | |
Gene Type | protein-coding | GO ID | GO:0001708 | UniProtAcc | O75333 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
347853 | TBX10 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.14e-02 | 1.36e-01 | -0.1808 |
347853 | TBX10 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 5.30e-01 | -0.2602 |
347853 | TBX10 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.08e-06 | 1.20e+00 | -0.2196 |
347853 | TBX10 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.71e-02 | 8.80e-02 | 0.3005 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBX10 | SNV | Missense_Mutation | rs765317926 | c.413N>A | p.Gly138Asp | p.G138D | O75333 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TBX10 | SNV | Missense_Mutation | c.213G>A | p.Met71Ile | p.M71I | O75333 | protein_coding | deleterious(0.02) | possibly_damaging(0.847) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
TBX10 | SNV | Missense_Mutation | c.22N>A | p.Gly8Ser | p.G8S | O75333 | protein_coding | tolerated_low_confidence(0.49) | benign(0.003) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TBX10 | SNV | Missense_Mutation | c.666N>T | p.Glu222Asp | p.E222D | O75333 | protein_coding | deleterious(0.02) | benign(0.275) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TBX10 | SNV | Missense_Mutation | c.851N>T | p.Ala284Val | p.A284V | O75333 | protein_coding | tolerated(0.51) | benign(0) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TBX10 | SNV | Missense_Mutation | rs150805271 | c.625N>T | p.Arg209Cys | p.R209C | O75333 | protein_coding | deleterious(0.01) | possibly_damaging(0.848) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
TBX10 | SNV | Missense_Mutation | novel | c.1024A>T | p.Arg342Trp | p.R342W | O75333 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TBX10 | SNV | Missense_Mutation | rs372763899 | c.440G>A | p.Arg147His | p.R147H | O75333 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TBX10 | deletion | Frame_Shift_Del | c.956delN | p.Pro319ArgfsTer20 | p.P319Rfs*20 | O75333 | protein_coding | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
TBX10 | SNV | Missense_Mutation | rs376880264 | c.601N>A | p.Val201Met | p.V201M | O75333 | protein_coding | deleterious(0.03) | probably_damaging(0.988) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |